This week we took a look at FDA-cleared and approved IVDs for oncology, and grouped them based on whether they measure proteins or nucleic acids. Protein-based tests have historically been the dominant type used in the clinic, but this is changing rapidly. Based on...
We have recently been focusing on the growth in the use of biomarkers in clinical trials, and today pulled data from BiomarkerBase to examine the growth in the number of unique biomarkers that are being used in the inclusion/exclusion criteria of active clinical...
Diagnostic tests with algorithms seem to slow review periods on average. Share this Image On Your Site <p><strong>Please include attribution to https://amplion.wpengine.com/biomarker-trends with this graphic.</strong><br /><br /><a...
As we have previously reported in this blog, innovation is not a major focus for many of the largest diagnostics companies. With but a few exceptions, the focus for the largest companies tends to be on selling instrumentation and on developing “me-too” tests, which...
Andrew Conrad, Head of Life Sciences at Google, announced last week at the Wall Street Journal Digital conference that Google is developing a wearable sensor that can receive signals from circulating nanoparticles. The nanoparticles are bound to antibodies against...